Skip to content
pharmaceutical hero image
pharmaceutical hero image


We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.

We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising. Our clients include Novartis, Pfizer, Bayer, Merck, GSK, and Johnson & Johnson among many others.

News and insights

Person wearing protective clothing and holding apparatus in science lab

Blog Post: 08 June 2022

Italy fines Leadiant EUR3.5 million for charging excessive prices for an orphan drug

On 31 May 2022, the Italian Competition Authority (ICA) published its decision sanctioning the pharmaceutical company Leadiant EUR3.5 million for charging excessive prices for the sale of an orphan…

Read more
Multiple test tubes and dropper

Publications: 27 April 2022

Webinar: Orange Book listing sheets under the microscope

Preparing the Orange Book listing sheet (i.e., Form FDA 3542) for a U.S. patent is more than just checking the boxes. 

Read more

News: 08 April 2022

Allen & Overy advises the lending banks syndicate on a EUR451 million financing in connection with the EUROAPI’s contemplated listing on Euronext Paris

Allen & Overy has advised the banking syndicate, composed of BNP Paribas, Bank of America, Crédit Agricole Corporate and Investment Bank, Deutsche Bank, J.P. Morgan, Natixis and Société Générale, on a…

Read more

Blog Post: 23 March 2022

New decisions in Europe and the US in CRISPR/Cas9 patent dispute

CRISPR/Cas technology, also known as “genetic scissor”, is one of the most targeted and promising tools in gene technology. It allows targeted and extremely precise modification of the DNA in humans,…

Read more

Download our sector brochure

Life sciences A&O red molecules

Our Life Sciences and Healthcare sector focus 2022

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.